- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
FDA panel says filler product labels should be strengthened
Washington - An FDA panel has decided that product labels on wrinkle fillers should be strengthened to include long-term effects, such as possible scarring, the Wall Street Journal reports.
Washington
- An FDA panel has decided that product labels on wrinkle fillers should be strengthened to include long-term effects, such as possible scarring, the Wall Street Journal reports.
The panel concluded that current product labels on fillers are inadequate, because they only discuss immediate and temporary side effects, such as swelling and redness, but that many serious and unexpected adverse events can occur, according to the agency.
The FDA conducted a review of adverse events in 930 reports. Of those, 823 were found to be injuries, including infection, bleeding, lumps or bumps in the face and in some cases disfigurement.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
